Spectris AD

Press Releases

Cognito Therapeutics Announces Non-invasive Neuromodulation Therapy Delays Alzheimer’s Disease Progression

–Cognito Therapeutics, a pioneering neurotechnology company developing disease-modifying therapies for neurodegenerative diseases, today announced new results from a post hoc analysis of its OVERTURE feasibility clinical trial showing that its investigational therapy, Spectris AD™, significantly slows the progression of Alzheimer’s disease. Spectris AD™ uses non-invasive neuromodulation through synchronized light and sound stimulation at a gamma frequency (40Hz) to restore brain electrical activity…